Cardiovascular · Small interfering RNA (siRNA)

Zerlasiran

Zerlasiran is a small interfering RNA that lowered lipoprotein(a) by more than 80% in Phase 2. Silence Therapeutics completed Phase 3 readiness in 2025 but no outcomes trial is registered, and in October 2026 Silence agreed to be acquired by Merck KGaA.

Not yet approvedPhase 2 complete; described by Silence as Phase 3-ready; Silence agreed to be acquired by Merck KGaA

Not yet approved: Not approved for any use. The drug is still being tested in clinical trials. About status badges

FDA: Not approved. No approved application appears in openFDA as of Nov 19, 2026 (openFDA lists approved applications only, so a pending submission would not appear). In the United States, this drug is investigational.

DeveloperSilence Therapeutics (partners: Merck KGaA, Darmstadt, Germany (pending acquisition of Silence)) · Silence Therapeutics pipeline
Drug typeSmall interfering RNA (siRNA)
TargetLPA gene (apolipoprotein(a)) mRNA
MechanismSilences the LPA gene's messenger RNA in the liver, reducing production of apolipoprotein(a) and lowering lipoprotein(a)
Other namesSLN360

Key points

  • Zerlasiran uses RNA interference to block production of apolipoprotein(a), lowering lipoprotein(a) [Lp(a)].
  • In a 178-patient Phase 2 trial, time-averaged placebo-adjusted Lp(a) reductions through week 36 were 81% to 86%, with median reductions at week 36 of 90% to 96%.
  • Silence Therapeutics reports that it completed Phase 3 readiness work in 2025. No Phase 3 trial of zerlasiran is listed on ClinicalTrials.gov.
  • Silence announced on October 19, 2026 that it had agreed to be acquired by Merck KGaA, Darmstadt, Germany, with closing expected in the first quarter of 2027 (company-reported).
  • Zerlasiran's next steps likely depend on the acquirer's plans and on how the Lp(a) field reads the 2026 pelacarsen failure.

Development programs

Each disease a drug is tested for is a separate program, with its own evidence and its own odds.

IndicationStageRegistered trialsHistorical benchmark
Elevated lipoprotein(a) with cardiovascular disease
Phase 2 is complete (registry). Silence describes Phase 3 readiness as completed in 2025 (company-reported). No Phase 3 trial is registered.
Phase 2 completed (Phase 3 not yet started)2
0 active · 2 completed
15.1% eventual approval
Phase 2 → Phase 3: 28.9%

Historical benchmarks are industry-wide averages for programs at the same stage, 2011–2020 (BIO, Informa, QLS; eventual-approval figures are from the report’s likelihood-of-approval table, Figure 5b). They are not predictions for this drug. We use all-indication rates because the source does not define which conditions fall in each disease area; see the therapeutic area pages for area-level rates. Benchmarks are withheld where they would mislead, for example after approval or after a failed pivotal trial. See our methodology.

What zerlasiran is

Zerlasiran is a small interfering RNA (siRNA) developed by Silence Therapeutics. Like olpasiran and lepodisiran, it silences the messenger RNA of the LPA gene in the liver, reducing production of apolipoprotein(a) and therefore of lipoprotein(a), or Lp(a). It is given by injection under the skin at intervals of several months.

Clinical evidence

Phase 1

A single- and multiple-dose study, published in JAMA in 2024, found no serious adverse events. In the multiple-dose group, with a median baseline Lp(a) of 288 nmol/L, two doses produced maximal median Lp(a) changes of −242 to −310 nmol/L across dose groups, compared with +19 nmol/L with placebo.

Phase 2

The Phase 2 trial enrolled 178 patients with a median baseline Lp(a) of 213 nmol/L. Published in JAMA in December 2024:

Regimen Time-averaged placebo-adjusted change, baseline to week 36 Median change at week 36
450 mg every 24 weeks −85.6% −94.5%
300 mg every 16 weeks −82.8% −96.4%
300 mg every 24 weeks −81.3% −90.0%

Source: Nissen et al., JAMA (2024).

The most common treatment-related adverse effects were injection-site reactions, mostly mild pain in 2.3% to 7.1% of participants on the day after dosing. There were 20 serious adverse events in 17 patients, none considered related to the study drug.

Development status

Zerlasiran's story since Phase 2 has been corporate rather than clinical:

  • Phase 3 readiness. Silence reports that its research costs fell in 2026 mainly because "zerlasiran Phase 3 readiness" was completed in 2025 (company-reported, November 2026 filing). No Phase 3 trial is listed on ClinicalTrials.gov.
  • Acquisition. On October 19, 2026, Silence announced a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, through a U.K. scheme of arrangement. The transaction is expected to close in the first quarter of 2027 (company-reported).

The sources we reviewed do not say what Merck KGaA plans for zerlasiran after the deal closes.

Scientific perspective

Zerlasiran's Phase 2 Lp(a) reductions are in the same range as other siRNAs and deeper than those achieved by pelacarsen in its failed outcomes trial. But no siRNA has yet shown that lowering Lp(a) reduces cardiovascular events. A Phase 3 outcomes trial would need to enroll thousands of patients and run for years, the same expensive, long-horizon test that pelacarsen did not pass.

Development perspective

  • Regulatory status: zerlasiran has no FDA approval.
  • Stage: Phase 2 complete, with no registered Phase 3. Programs moving from Phase 2 to Phase 3 have historically advanced only about 29% of the time, and about 15% have reached approval. Here the gating decision may be strategic rather than scientific. See What Are the Chances of FDA Approval After Phase 2?
  • What to watch: the acquirer's first public statements about the program after closing, and whether a Phase 3 trial is registered.

Competitive context

Zerlasiran would enter Phase 3 well behind Amgen's olpasiran and Lilly's lepodisiran, whose outcomes trials are already fully enrolled or running. Its value to a new owner may depend on whether those earlier trials succeed, and on whether zerlasiran's dosing or profile offers an advantage.

Development timeline

  1. Dec 13, 2022Phase 2 trial in patients with elevated Lp(a) at high risk of cardiovascular events begins. Registry
  2. May 14, 2024Phase 1 single- and multiple-dose results published in JAMA. Peer-reviewed
  3. Dec 17, 2024Phase 2 results published: time-averaged Lp(a) reductions of 81% to 86% versus placebo through week 36. Peer-reviewed
  4. Sep 4, 2026Read-across: pelacarsen, another Lp(a)-lowering drug, misses the primary endpoint of its Phase 3 outcomes trial. Company-reported
  5. Oct 19, 2026Silence Therapeutics announces an agreement to be acquired by Merck KGaA, Darmstadt, Germany; closing expected in Q1 2027. Company-reported

What could change the outlook

  • Completion of Merck KGaA's acquisition of Silence, expected in Q1 2027 (company-reported), and any statement about zerlasiran's development plans.
  • Registration of a Phase 3 cardiovascular outcomes trial on ClinicalTrials.gov.
  • Results of other Lp(a) outcomes trials (olpasiran, lepodisiran), which will determine how attractive the class is for further investment.
  • Any change in Silence's description of the program in its remaining SEC filings before the deal closes.

Latest company disclosures

Company press releases (SEC filings and PR Newswire) that mention Zerlasiran. Company-reported, not independently verified.

  1. Quarterly reportCompany-reportedNov 12, 2026

    Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results

    The $11.2 million decrease is mainly due to the zerlasiran Phase 3 readiness being completed in 2025 as well as reduced personnel costs. • G&A Expenses: General and administrative (G&A) expenses were $4.9 million for the three months ended September 30, 2026, compared to $5.8 million for the three months ended...

    Source
    SEC Form 8-K · Financial results
  2. Quarterly reportCompany-reportedAug 10, 2026

    Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

    The $8.4 million decrease is mainly due to the zerlasiran Phase 3 readiness being completed in 2025 as well as reduced personnel costs. • G&A Expenses: General and administrative (G&A) expenses were $4.7 million for the three months ended June 30, 2026, compared to $5.1 million for the three months ended June 30...

    Source
    SEC Form 8-K · Financial results
  3. Investor presentationCompany-reportedJun 23, 2026

    June 2026 Corporate Presentation EXHIBIT 99.1

    Silencing diseases through precision engineered medicines created with proprietarysiRNA technology We are Silencing Genes to Treat Disease Natural: RNAi is a natural biological process that regulates gene expression Precise: each siRNA is intentionally designed to bind only to the target gene transcript Durable...

    Source
    SEC Form 8-K · Regulation FD disclosure

All Zerlasiran disclosures in Pipeline News

Clinical trials

2 registered trials list Zerlasiran as an intervention, retrieved from ClinicalTrials.gov on Nov 19, 2026. Status, dates, and enrollment are as reported by sponsors to the registry. “Est.” marks anticipated values.

Elevated lipoprotein(a) with cardiovascular disease

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT05537571
Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
Phase 2Completed180Jan 11, 2024Yes
1 Phase 1 or other early-stage study
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT04606602
Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)
Phase 1Completed70Aug 23, 2023No

No registry changes detected since tracking began on Nov 19, 2026. Future status, date, and endpoint changes will be logged here.

Sources

  1. Nissen SE, et al. Zerlasiran, a small-interfering RNA targeting lipoprotein(a): a Phase 2 randomized clinical trial. JAMA. 2024;332(23):1992–2002.Peer-reviewed
  2. Nissen SE, et al. Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial. JAMA. 2024;331(18):1534–1543.Peer-reviewed
  3. Silence Therapeutics plc. Form 8-K, Exhibit 99.1: third-quarter 2026 results and acquisition update (November 12, 2026).Company-reported
  4. ClinicalTrials.gov. Zerlasiran Phase 2 trial (NCT05537571).Registry
  5. Clarke R, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. New England Journal of Medicine. 2009;361(26):2518–2528.Peer-reviewed
  6. American Heart Association Newsroom. Lp(a) HORIZON trial results (AHA Scientific Sessions 2026).Scientific meeting
  7. BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report

This profile is for education and research. It is not medical advice and not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported results are labeled and have not necessarily been peer reviewed. See our editorial standards and disclaimer.